Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 1, 1998, Pages 71-76

  Beale, P ^a   Judson, I ^a   Hanwell, J ^a   Berry, C ^a   Aherne, W ^a   Hickish, T ^a   Martin, P ^b   Walker, M ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Pharmacokinetics; Phase I trial; Raltitrexed; Thymidylate synthase inhibitors

Indexed keywords

CARBON 14; RALTITREXED; THYMIDYLATE SYNTHASE INHIBITOR;

ADENOCARCINOMA; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; ERYTHROCYTE LEVEL; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; SOLID TUMOR; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; CARBON RADIOISOTOPES; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; QUINAZOLINES; RADIOPHARMACEUTICALS; THIOPHENES; THYMIDYLATE SYNTHASE;

EID: 0031978715     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050787     Document Type: Article

References (14)

1. Aherne GW, Farrugia DC, Ward E, Sutcliffc F, Jackman AL (1995) ZD1694 (Tomudex) and polyglutamate levels in mouse plasma and tissues measured by radioimmunoassay and the effect of leucovorin. Proc Am Assoc Cancer Res 36: 376
2. Clarke SJ, Hanwell J, Boer M de, Planting A, Verweij J, Walker M, Smith R, Jackman AL, Hughes LR, Harrap KR, Kennealey GT, Judson IR (1996) Phase I trial of ZD1694 ("Tomudex"), a new folate based, thymidylate synthase inhibitor. J Clin Oncol 14: 1495
3. Cunningham D, Zalcherg JR, Rath U, Olver I, Van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G, Azab M, Seymour L, Lowery K, the "Tomudex" Colorectal Cancer Study Group (1995) "Tomudex" (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 31A: 1945
4. Gore ME, Earl HM, Cassidy J, Tattersall M, Mansi J, Seymour L, Azab M (1995) A phase II study of Tomudex in relapsed epithelial ovarian cancer. Ann Oncol 6/7: 724
5. Heaven R, Bowen K, Rinaldi D, Robert F, Jenkins T, Eckardt J, Fields S, Hardy J, Patton S, Kennealey G (1994) An open phase II trial of ZD1694, a thymidylate synthase inhibtor, in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 13: A1191
6. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR, Hughes LR (1991) ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumour cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 51: 5579
7. Jackman AL, Farrugia DC, Gibson W, Kimbell R, Harrap KR, Stephens TC, Azab M, Boyle FT (1995) ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer 31A: 1277
8. Jodrell D, Newell D, Gibson W, Hughes L, Calvert A (1991) The pharmacokinetics of the quinazoline antifolate ICT D 1694 in mice and rats. Cancer Chemother Pharmacol 28: 331
9. Judson IR, Aherne GW, Maughan T, Cunningham D, Hanwell J, Berry C, Walker M (1996) Pharmacokinetic studies with Tomudex (ZD1694). Ann Oncol 7 [Suppl 1]: 304
10. Pazdur R, Casper ES, Merepol NJ, Fuchs C, Kennealey GT (1994) Phase II study of Tomudex (ZD1694). a thymidylate synthase inhibitor, in advanced pancreatic cancer. Proc Am Soc Clin Oncol 13: 207
11. Schalhorn A, Sauer H, Wilmans W, Stupp-Poutout G (1982) Pharmacokinetics of erythrocyte methotrexate after high dose methotrexate. Cancer Chemother Pharmacol 9: 65
12. Smith I, Jones A, Spielman M, Namer M, Green MD, Bonneterre J, Wander HE, Hatseek T, Wilking N, Zalcbergn J, Spiers J, Seymour L (1996) A phase II study in advanced breast cancer: ZD1694 ("Tomudex"), a novel direct and specific thymidylate synthetase inhibitor. Br J Cancer 74: 479
13. Synold TW, Newman EH, Doroshow JH, Muggia FM (1996) Plasma and red blood cell pharmacokinetics of lometrexol given every 21 days: correlation between RBC, LOM levels and cumulative toxicity. Ann Oncol 7 [Suppl 1]: 312
14. Zalcberg JR, Cunningham D, Van-Cutsem E, Francois E, Schornagel J, Adenis A, Green M, Iveson A, Azab M, Seymour I (1996) ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 14: 716